Barbara Arzymanow is a founding director of an independent healthcare
consultancy firm, True Research Limited, established in 1999. She is an investment analyst specialising in Pharmaceuticals, prior to which she carried out academic medical research in university laboratories. Her experience, obtained entirely from outside
the pharmaceutical industry, gives her a unique perspective independent of commercial lobbies. She has extensive experience in financing the biotechnology industry, which is vital for the long-term standing of medical research in the UK. She has always been inspired by the scientific excellence within the UK and would like to see collaborations between industry, the NHS and academia strengthened.
Her interests include all areas of the NHS and healthcare, especially pharmaceuticals, science, R&D and financial matters. She has been a director at Kleinwort Benson and Robert Fleming (investment banks). In the early 1980's she was an author of a number of publications in medical journals. In the second half of the 1980's and early 1990's her pharmaceutical investment analysis team was consistently voted as the best in the UK (e.g. in the annual Extel Survey). She played significant corporate finance roles in the first major transatlantic drug industry merger (SmithKline with Beecham) and in the flotation of the first biotechnology company on the London Stock Exchange.
Barbara is an Associate
of the think tank 2020health. Her blogs have been viewed the most of those published by 2020health (total all-time visits) and can be found here. Her Tweets on Twitter are available here.
Since the General Election a number of Barbara Arzymanow's published suggestions have been in line with policy subsequently announced by Government.
Barbara's interests outside healthcare include politics and work (largely charitable) involving the Polish community in London. She is active in local politics, a Management Committee Member of Polish YMCA (Polska YMCA) and a governor of two schools close to where she lives.